Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Aptevo Therapeutics stock

Learn how to easily invest in Aptevo Therapeutics stock.

Aptevo Therapeutics Inc is a biotechnology business based in the US. Aptevo Therapeutics shares (APVO) are listed on the NASDAQ and all prices are listed in US Dollars. Aptevo Therapeutics employs 54 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in Aptevo Therapeutics

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – APVO – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.
Client disclaimer: US Brokerage services through eToro USA Securities Inc, member of FINRA, SIPC. Crypto assets through eToro USA LLC.

Aptevo Therapeutics stock price (NASDAQ: APVO)

Use our graph to track the performance of APVO stocks over time.

Aptevo Therapeutics shares at a glance

Information last updated 2022-07-01.
Latest market close$3.58
52-week range$3.03 - $22.50
50-day moving average $4.31
200-day moving average $7.96
Wall St. target price$28.00
PE ratio N/A
Dividend yield $0 (0%)
Earnings per share (TTM) $-6.00

Buy Aptevo Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
1 - 5 of 5
Name Product Asset types Stock trade fee Minimum deposit Signup bonus
Finder Award
eToro
Stocks, ETFs, Cryptocurrency
$0
$10
$10
when you sign up and deposit $100
Trade stocks in the app or online with $0 commissions. Not available in NY, NV, MN, or TN.
Client disclaimer: US Brokerage services through eToro USA Securities Inc, member of FINRA, SIPC. Crypto assets through eToro USA LLC.
SoFi Invest
Stocks, ETFs, Cryptocurrency
$0
$1
$10 - $100
when you open an account and place a first crypto trade of $50 - $5,000+
A free way to invest in most equities.
Tastyworks
Stocks, Options, ETFs, Cryptocurrency
$0
$0
$200 in US stocks
when you open and fund an account with min. $2,000 for 3+ mos.
Trade stocks, options, ETFs and futures on mobile or desktop with this advanced platform.
JPMorgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$0
$0
$125 - $625
when you open and fund an account with $25,000 - $250,000+
INVESTMENT AND INSURANCE PRODUCTS ARE: NOT A DEPOSIT • NOT FDIC INSURED • NO BANK GUARANTEE • MAY LOSE VALUE
Axos Bank Self Directed Investing
Stocks
$0
$1,000
$150
when you open an account and deposit at least $1500.
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Aptevo Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Aptevo Therapeutics price performance over time

Historical closes compared with the close of $3.58 from 2022-07-01

1 week (2022-06-27) -1.92%
1 month (2022-06-02) -24.15%
3 months (2022-04-01) -43.17%
6 months (2022-01-04) -54.63%
1 year (2021-07-02) -83.29%
2 years (2020-07-02) -61.00%
3 years (2019-07-03) 325.33%
5 years (2017-07-03) 74.63%

Aptevo Therapeutics financials

Revenue TTM $13 million
Gross profit TTM $12.3 million
Return on assets TTM -22.08%
Return on equity TTM -1281.95%
Profit margin -222.55%
Book value $0.25
Market capitalisation $17.9 million

TTM: trailing 12 months

Aptevo Therapeutics share dividends

We're not expecting Aptevo Therapeutics to pay a dividend over the next 12 months.

Have Aptevo Therapeutics's shares ever split?

Aptevo Therapeutics's shares were split on a 1:14 basis on 26 March 2020. So if you had owned 14 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Aptevo Therapeutics shares – just the quantity. However, indirectly, the new 1300% higher share price could have impacted the market appetite for Aptevo Therapeutics shares which in turn could have impacted Aptevo Therapeutics's share price.

Aptevo Therapeutics share price volatility

Over the last 12 months, Aptevo Therapeutics's shares have ranged in value from as little as $3.03 up to $22.5. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Aptevo Therapeutics's is 6.3367. This would suggest that Aptevo Therapeutics's shares are significantly more volatile than the average for this exchange and represent a higher risk.

Aptevo Therapeutics overview

Aptevo Therapeutics Inc. , a clinical-stage biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. Its lead clinical candidate is APVO436, a bispecific T-cell engaging antibody candidate that is in Phase 1b clinical trial for acute myelogenous leukemia and myelodysplastic syndrome. The company's preclinical candidates also include ALG. APV-527, an investigational bispecific ADAPTIR candidate that features a mechanism of action to target 4-1BB (CD137) and 5T4, a tumor antigen expressed in various types of cancers; and APVO603, a dual agonist bispecific antibody to target 4-1BB and OX40. It also develoes APVO442, a bispecific candidate based on the ADAPTIR-FLEX platform technology to enhance biodistribution of drugs to PSMA positive tumors for treatment of prostate cancer. The company has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.

Frequently asked questions

What percentage of Aptevo Therapeutics is owned by insiders or institutions?
Currently 1.137% of Aptevo Therapeutics shares are held by insiders and 17.499% by institutions.
How many people work for Aptevo Therapeutics?
Latest data suggests 54 work at Aptevo Therapeutics.
When does the fiscal year end for Aptevo Therapeutics?
Aptevo Therapeutics's fiscal year ends in December.
Where is Aptevo Therapeutics based?
Aptevo Therapeutics's address is: 2401 4th Avenue, Seattle, WA, United States, 98121
What is Aptevo Therapeutics's ISIN number?
Aptevo Therapeutics's international securities identification number is: US03835L2079
What is Aptevo Therapeutics's CUSIP number?
Aptevo Therapeutics's Committee on Uniform Securities Identification Procedures number is: 03835L108

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site